BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study
Phase of Trial: Phase III
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Muscle spasticity
- Focus Adverse reactions; Registrational
- Sponsors Allergan
- 10 Jun 2015 Planned End Date changed from 1 Jul 2017 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
- 10 Jun 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
- 22 Dec 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2012-000084-24)